Neumirna Therapeutics is a pharmaceutical company that develops therapeutics for the treatment of neurological diseases.
Neumirna Therapeutics has raised $20.6M in total funding. The most recent round was Series A. The last funding was announced in January 2025.
Neumirna Therapeutics's investors include Innovestor, Invivo Capital Partners, Angelini Ventures.
Neumirna Therapeutics is headquartered in Copenhagen, Denmark.
Neumirna Therapeutics is a pharmaceutical company that develops therapeutics for the treatment of neurological diseases.
Neumirna Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Neumirna Therapeutics — Funding & Investors." VCBacked, January 8, 2025, https://www.vcbacked.co/company/neumirna-therapeutics. Accessed September 15, 2026.
VCBacked. (2025). Neumirna Therapeutics — Funding & Investors. Retrieved September 15, 2026, from https://www.vcbacked.co/company/neumirna-therapeutics
{{cite web |title=Neumirna Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/neumirna-therapeutics |website=VCBacked |access-date=September 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated